Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for rheumatoid arthritis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Adalimumab (Hyrimoz) - Juvenile RheumatoidArthritis, Psoriatic Arthritis, RheumatoidArthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how (...) human monoclonal antibody produced in Chinese Hamster Ovary cells. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear to slightly opalescent, colourless to slightly yellowish solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Rheumatoidarthritis Hyrimoz in combination with methotrexate, is indicated for: • the treatment of moderate to severe, active rheumatoidarthritis in adult patients when the response to disease
Drug Therapy for Early RheumatoidArthritis: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE Drug Therapy for Early RheumatoidArthritis: A Systematic Review Update July 2018 In partnership withComparative Effectiveness Review Number 211 Drug Therapy for Early RheumatoidArthritis: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov and Patient (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact email@example.com. Suggested citation: Donahue KE, Gartlehner G, Schulman ER, Jonas B, Coker-Schwimmer E, Patel SV, Weber RP, Lohr KN, Bann C, Viswanathan M. Drug Therapy for Early RheumatoidArthritis: A Systematic Review Update. Comparative Effectiveness Review No. 211. (Prepared by the RTI International–University of North Carolina
Rheumatoidarthritis Top results for rheumatoidarthritis - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (...) (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for rheumatoidarthritis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials
Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoidarthritis: associations to future good radiographic and physical outcomes To explore associations between remission, based on clinical and ultrasound definitions, and future good radiographic and physical outcome in early rheumatoidarthritis (RA).Newly diagnosed patients with RA followed a treat-to-target strategy incorporating ultrasound information in the Aiming for Remission in rheumatoid (...) arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen (ARCTIC) trial. We defined 6-month remission according to Disease Activity Score, Disease Activity Score in 28 joints-erythrocyte sedimentation rate, American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean criteria, Simplified Disease Activity Index, Clinical Disease Activity Index and two ultrasound definitions (no power Doppler signal, grey scale score ≤2). Two outcomes
Treatment of rheumatoidarthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate The objective of this study was to assess the treatment for patients with rheumatoidarthritis (RA) in the USA.This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort
Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in RheumatoidArthritis Patients with and without Baseline CV Disease To evaluate the cardiovascular safety of abatacept (ABA) versus tumor necrosis factor inhibitors (TNFi) in rheumatoidarthritis (RA) patients with and without underlying cardiovascular disease (CVD).We identified RA patients with and without baseline CVD who initiated ABA or TNFi by using data from 2 large US insurance claims databases: Medicare
Rheumatoidarthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink To examine temporal trends in all-cause and cause-specific mortality in RA.Data from the Clinical Practice Research Datalink were used. Incident RA cases and four age-, sex- and general practice-matched controls were identified from at-risk cohorts for each calendar year and followed-up for up to 5 years. Mortality rates and 95% CIs were computed. Cox
Rheumatoidarthritis Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4
Tofacitinib (rheumatoidarthritis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.8 of the dossier assessment Tofacitinib (RheumatoideArthritis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 July 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-18 (...) Tofacitinib (rheumatoidarthritis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-18 Version 1.0 Tofacitinib (rheumatoidarthritis) 28 July 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Tofacitinib (rheumatoidarthritis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded
Baricitinib (Olumiant) - To treat moderately to severely active rheumatoidarthritis Drug Approval Package: Olumiant (baricitinib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Olumiant (baricitinib) Company: Eli Lilly and Company Application Number: 207924 Approval Date: 05/31/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA
Use of the Orem self-care model on pain relief in women with rheumatoidarthritis: a randomized trial Self-care is an important tool in controlling pain in patients with rheumatoidarthritis. The aim of this study was to determine the use of the Orem self-care model on pain relief in patients with rheumatoid arthritis.This was a clinical trial performed on 60 patients with rheumatoidarthritis who referred to a rheumatology clinic in Karaj during 2013-2015 (30 patients in the control group (...) showed a significant difference in three measures of pain in the intervention group (p=0.001), while in the control group, this difference was not significant (p=0.59).According to the results, the Orem self-care model is effective in reducing pain in patients with rheumatoidarthritis Therefore, applying the Orem self-care model is recommended to promote and maintain self-care behavior in patients with rheumatoid arthritis.The trial was registered at the Iran Registry of Clinical Trials (http
Safety and efficacy of upadacitinib in patients with rheumatoidarthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoidarthritis. We aimed to assess the efficacy of upadacitinib in patients with inadequate response to conventional (...) synthetic disease-modifying anti-rheumatic drugs (csDMARDs).This study is a double-blind, placebo-controlled trial at 150 sites in 35 countries. We enrolled patients aged 18 years or older with active rheumatoidarthritis for 3 months or longer, who had received csDMARDs for at least 3 months with a stable dose for at least 4 weeks before study entry, and had an inadequate response to at least one of the following csDMARDs: methotrexate, sulfasalazine, or leflunomide. Using interactive response
2018LancetControlled trial quality: predicted high
Safety and efficacy of upadacitinib in patients with active rheumatoidarthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoidarthritis. We did this study to further assess the safety and efficacy of upadacitinib in patients with an inadequate (...) response to biologic disease-modifying anti-rheumatic drugs (bDMARDs).We did this double-blind, randomised controlled phase 3 trial at 153 sites in 26 countries. Patients were aged 18 years or older, had active rheumatoidarthritis and previous inadequate response or intolerance to bDMARDs, and were receiving concomitant background conventional synthetic DMARDS (csDMARDs). We randomly assigned patients (2:2:1:1) by interactive response technology to receive once-daily oral extended-release upadacitinib
2018LancetControlled trial quality: predicted high
Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoidarthritis: development and validation of clinical predictors To identify and validate clinical baseline predictors associated with inadequate response (IR) to methotrexate (MTX) therapy in newly diagnosed patients with rheumatoidarthritis (RA).In U-Act-Early, 108 disease-modifying antirheumatic drug (DMARD)-naive patients with RA were randomised to initiate MTX therapy and treated to target until (...) sustained remission (disease activity score assessing 28 joints (DAS28) <2.6 with four or less swollen joints for ≥24 weeks) was achieved. If no remission, hydroxychloroquine was added to the treatment regimen (ie, 'MTX+') and replaced by tocilizumab if the target still was not reached thereafter. Regression analyses were performed to identify clinical predictors for IR, defined as needing addition of a biological DMARD, to 'MTX+'. Data from the treatment in the Rotterdam Early Arthritis Cohort were
Infliximab (Zessly) - Psoriatic Arthritis, RheumatoidArthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis 22 March 2018 EMA/223369/2018 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Zessly International non-proprietary name: infliximab Procedure No. EMEA/H/C/004647/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU (...) Institute ND Not done NS No sample NSAID Nonsteroidal anti-inflammatory drug OBS Observed data PAAP Patient’s Assessment of Arthritis Pain PD Pharmacodynamic(s) PE Physical examination PGA Patient’s Global Assessment of Arthritis PGAA Physician’s Global Assessment of Arthritis PIPD Potentially important protocol deviation PMDA Pharmaceuticals and Medical Devices Agency PK Pharmacokinetic(s) PP Per-Protocol PT Preferred term QC Quality control RA Rheumatoidarthritis RNA Ribonucleic acid SAE Serious
Serum heat-shock protein-65 antibody levels are elevated but not associated with disease activity in patients with rheumatoidarthritis and ankylosing spondylitis Heat-shock proteins (HSPs) have gained increased interest for their role in autoimmune disorders. These proteins are targeted by the immune system in various autoimmune diseases. The aim of this study was to assess the serum heat-shock protein-65 antibody (anti-HSP65) levels and their clinical significance in patients with rheumatoid (...) arthritis (RA) and ankylosing spondylitis (AS).A total of 30 patients with RA, 30 patients with AS, and 30 healthy controls were enrolled in this study. All patients were assessed using routine clinical and laboratory evaluations. Serum anti-HSP65 levels were determined by ELISA.Serum anti-HSP65 levels of both RA and AS patients were significantly higher than those of controls (p=0.014 and p=0.001, respectively). No association was found between serum anti-HSP65 levels and disease activity in either RA